|
Market Closed -
Nasdaq
20:00:00 30/10/2026 GMT
|
5-day change | 1st Jan Change | ||
| 6.940 USD | +4.52% |
|
+12.12% | +66.03% |
| 10-30 | US FDA approves Inovio's treatment for rare throat disease; shares surge | RE |
| 10-30 | US FDA approves Inovio's treatment for rare throat disease | RE |
| Market Cap | 2.48B 2.23B 2.05B 1.85B 3.47B 236B 3.53B 24.41B 9.8B 124B 9.33B 9.13B 391B | P/E 2026 * |
32.2x | P/E 2027 * | 11.2x |
|---|---|---|---|---|---|
| Enterprise Value | 2.48B 2.23B 2.05B 1.85B 3.47B 236B 3.53B 24.41B 9.8B 124B 9.33B 9.13B 391B | EV / Sales 2026 * |
10.5x | EV / Sales 2027 * | 5.68x |
| Free-Float |
87.36% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| PGEN | Delayed | |
CBOE
| PGEN | Real-time | |
|
Tradegate
| I5X | Real-time | |
|
Berne S.E.
| I5X | End-of-day quote | |
|
Boerse Muenchen
| I5X | Real-time | |
|
Deutsche Boerse AG
| I5X | Delayed | |
|
Börse Stuttgart
| I5X | Delayed |
Last Transcript: Precigen, Inc.
| 1 day | +4.52% | ||
| 1 week | +12.12% | ||
| 1 month | -18.93% | ||
| 3 months | +10.69% | ||
| 6 months | +66.83% | ||
| Current year | +66.03% |
| 1 week | 5.96 |  | 7.04 |
| 1 month | 5.96 | | 8.6 |
| Current year | 3.04 | | 8.98 |
| 1 year | 3.04 | | 8.98 |
| 3 years | 0.65 | | 8.98 |
| 5 years | 0.65 | | 8.98 |
| 10 years | 0.65 | | 32.9 |
| Manager | Title | Age | Since |
|---|---|---|---|
Helen Sabzevari
CEO | Chief Executive Officer | 64 | 31/12/2019 |
Harry Thomasian
DFI | Director of Finance/CFO | 64 | 30/09/2021 |
Amy Lankford
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Randal Kirk
CHM | Chairman | 72 | 31/01/2008 |
Cesar Alvarez
BRD | Director/Board Member | 78 | 31/01/2008 |
Jeffrey Kindler
BRD | Director/Board Member | 70 | 27/11/2011 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 23/09/26 | Exercice | Chief Financial Officer | 107,330 | 0.0360% | ||
| 26/08/26 | Sell | Director | -185,000 | 0.0620% | ||
| 25/08/26 | Exercice | Executive/Senior Manager | 237,498 | 0.0796% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +4.52% | +12.12% | +67.63% | +514.16% | 2.48B | |
| +3.19% | +11.31% | +64.28% | +155.91% | 1,263B | |
| -0.73% | +3.56% | +44.65% | +84.17% | 658B | |
| +1.41% | +3.24% | +35.25% | +108.88% | 521B | |
| +0.42% | +3.20% | +55.81% | +72.50% | 391B | |
| +2.18% | +2.93% | +73.90% | +45.59% | 369B | |
| +1.12% | +4.52% | +34.76% | +58.24% | 307B | |
| +6.96% | +8.86% | +11.95% | +36.20% | 290B | |
| +1.15% | +6.09% | +56.15% | +82.25% | 252B | |
| +3.06% | +9.38% | +42.48% | +117.32% | 212B | |
| Average | +2.33% | +6.52% | +48.69% | +127.52% | 426.44B | |
| Weighted average by Cap. | +2.01% | +6.60% | +50.52% | +100.68% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 236M 211M 194M 176M 329M 22.39B 335M 2.32B 930M 11.78B 885M 866M 37.15B | 437M 391M 360M 326M 610M 41.5B 621M 4.29B 1.72B 21.83B 1.64B 1.61B 68.85B |
| Net income | 83.46M 74.75M 68.76M 62.3M 116M 7.92B 119M 820M 329M 4.17B 313M 307M 13.15B | 240M 215M 198M 179M 335M 22.77B 341M 2.36B 946M 11.98B 900M 881M 37.78B |
| Net Debt | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/10/26 | US$6.940 | +4.52% | 8,104,564 |
| 29/10/26 | US$6.640 | +9.21% | 7,742,783 |
| 28/10/26 | US$6.080 | -1.14% | 3,673,952 |
| 27/10/26 | US$6.150 | +1.82% | 3,790,136 |
| 26/10/26 | US$6.040 | -2.42% | 2,547,296 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- PGEN Stock
Select your edition
All financial news and data tailored to specific country editions
